High-dose cyclophosphamide can induce severe cardiomyopathy and fatal hemorrhagic myocarditis, necessitating early detection and potentially mechanical circulatory support.
Answers are grounded in this paper and cite their sources.
May warrant vigilance for cyclophosphamide cardiotoxicity; leaves open optimal risk stratification and support strategies.
Cyclophosphamide is increasingly used to treat various types of cancers and autoimmune conditions. Higher doses of this drug may produce significant cardiac toxicity, including fatal hemorrhagic myocarditis. In this review, we present a case of cyclophosphamide-induced cardiomyopathy requiring mechanical circulatory support. We also describe the pathophysiology, clinical manifestations, and risk factors for this important clinical entity and propose early detection and management strategies.
No takes yet. Share an insight, caveat, or question.
Dhesi et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: